Holen Sie sich die Stockscreener-App
3.3726
0.30%
-0.0074
Ironwood Pharmaceuticals Inc Aktie (IRWD) Neueste Nachrichten
IRWD vs. PBYI: Which Small-Cap Biotech Stock Is a Better Buy? - TradingView
Ironwood Pharmaceuticals, Inc. 8-K SEC Filing Details – Company Information, Address, and Nasdaq Listing - Minichart
Ironwood Pharmaceuticals confirms liquidity conditions for credit facility maturity - Investing.com
Ironwood Pharma Maintains Revolving Credit Facility to 2028 - TipRanks
Ironwood Pharmaceuticals Satisfies Liquidity Conditions In Credit Agreement On March 10 - TradingView
Investment Review: Can Ironwood Pharmaceuticals Inc stock double in the next yearJuly 2025 Price Swings & Weekly High Momentum Picks - baoquankhu1.vn
Aug Reactions: Will Ironwood Pharmaceuticals Inc outperform the market in YEAR2025 Buyback Activity & Safe Capital Investment Plans - baoquankhu1.vn
Will Linzess Continue to Aid IRWD's Top Line in 2026 After a Soft Q4? - Nasdaq
Ironwood Pharmaceuticals to Participate in The Citizens Life Sciences Conference - itemonline.com
US Stocks Recap: Does Ironwood Pharmaceuticals Inc have declining or rising EPSJuly 2025 Catalysts & Risk Controlled Daily Trade Plans - baoquankhu1.vn
Gains Report: Can Ironwood Pharmaceuticals Inc stock double in the next yearPrice Action & Target Return Focused Stock Picks - baoquankhu1.vn
IRWD Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat
IRWD Should I Buy - Intellectia AI
Ironwood Pharmaceuticals (NASDAQ:IRWD) Stock Price Down 10.1%Time to Sell? - MarketBeat
Ironwood Pharmaceuticals (NASDAQ:IRWD) Cut to "Hold" at Zacks Research - MarketBeat
Ironwood Pharmaceuticals (NASDAQ:IRWD) Plays Key Role In Nasdaq Futures Healthcare - Kalkine Media
Jefferies Maintains Hold on Ironwood Pharmaceuticals (IRWD) Feb 26, 2026 - Meyka
A Look At Ironwood Pharmaceuticals (IRWD) Valuation After Q4 2025 Results And 2026 Revenue Guidance - Yahoo Finance
Ironwood Pharmaceuticals (NASDAQ:IRWD) Posts Earnings Results, Misses Estimates By $0.03 EPS - MarketBeat
Ironwood Pharmaceuticals: Downgrading On Pipeline Setback And Extended Timeline For Apraglutide - Seeking Alpha
Jefferies raises Ironwood Pharmaceuticals stock price target on Linzess outlook - Investing.com Canada
IRWD Q4 Earnings and Revenues Fall Shy of Estimates, Stock Tanks - Finviz
IRWD: Analyst Raises Price Target and Maintains Rating | IRWD St - GuruFocus
Ironwood Pharmaceuticals (NASDAQ:IRWD) Stock Price Up 9.5% on Analyst Upgrade - MarketBeat
Ironwood Pharmaceuticals (NASDAQ:IRWD) Price Target Raised to $10.00 at Citizens Jmp - MarketBeat
GSA Capital Partners LLP Has $405,000 Stock Holdings in Ironwood Pharmaceuticals, Inc. $IRWD - MarketBeat
Ironwood Pharmaceuticals (IRWD) Margin Rebound Challenges Bearish Narratives Despite Softer Revenue - simplywall.st
Ironwood (IRWD) Q4 2025 Earnings Call Transcript - The Globe and Mail
Ironwood Pharmaceuticals Q4 2025 Earnings Call Transcript - MarketBeat
Ironwood Pharmaceuticals Balances Growth Plans With Pricing Risks - TipRanks
Ironwood Pharmaceuticals Inc (IRWD) Q4 2025 Earnings Call Highli - GuruFocus
Ironwood (NASDAQ: IRWD) chief auto-sells 36,492 shares for tax withholding - Stock Titan
Ironwood Pharmaceuticals (IRWD) officer sells shares to cover tax withholding - Stock Titan
Ironwood Pharmaceuticals Q4 Earnings Call Highlights - MarketBeat
Ironwood Pharmaceuticals, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:IRWD) 2026-02-25 - Seeking Alpha
Ironwood Pharmaceuticals Faces Tumultuous Week Amid Market Volatility - StocksToTrade
Ironwood Pharmaceuticals (NASDAQ:IRWD) Shares Gap DownWhat's Next? - MarketBeat
Ironwood Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Ironwood Pharmaceuticals (IRWD) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance
Ironwood Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Earnings call transcript: Ironwood Pharmaceuticals Q4 2025 misses forecasts, shares drop - Investing.com Australia
Earnings call transcript: Ironwood Pharmaceuticals Q4 2025 misses forecasts, shares drop By Investing.com - Investing.com South Africa
IRWD: 2026 guidance targets >$1.1B LINZESS sales and pivotal apraglutide Phase III launch - TradingView
Form 8K Ironwood Pharmaceuticals Inc For: 25 February By Investing.com - Investing.com Australia
Ironwood Pharmaceuticals (IRWD) Targets Over $300M Adjusted EBIT - GuruFocus
Ironwood (IRWD) Reports Q4 Revenue Below Expectations - GuruFocus
Ironwood Pharmaceuticals, Inc. Reiterates Earnings Guidance for the Year 2026 - marketscreener.com
Ironwood Pharmaceuticals officially released its financial report for the fourth quarter and full year of 2025 today. - Bitget
IRONWOOD PHARMACEUTICALS ($IRWD) Releases Q4 2025 Earnings - Quiver Quantitative
Form 8K Ironwood Pharmaceuticals Inc For: 25 February - Investing.com India
Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Results; Achieves 2025 Financial Guidance and Reiterates Strong 2026 Outlook - The AI Journal
Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Results - TradingView
Ironwood Pharmaceuticals (IRWD) posts 2025 results and raises 2026 EBITDA outlook - Stock Titan
Ironwood: Q4 Financial Overview - Bitget
Insights into Ironwood Pharmaceuticals's Upcoming Earnings - Benzinga
0.66%
1.22%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):